title: [The effect of fufang zhenzhu tiaozhi capsule on lipid metabolism in atherosclerotic rabbits].
abstract: OBJECTIVE
  To observe the effect of fufang zhenzhu tiaozhi capsule (FTZ) on lipid metabolism in atherosclerotic rabbits.
  
  
  METHODS
  50 rabbits were divided into five groups: normal control group, model group, simvastatin group, the high-dose group and low-dose group of FTZ. The atherosclerotic model was established by feeding the rabbits with high fat diet. The medicine interfered groups were administrated with homologous medicine on the base of high fat diet. All the rabbits were fed for 12 weeks. The blood lipids levels were determined just before the experiment and at the forth, the eighth and the twelfth weekend of the experiment. At the end of the experiment, serum apolipoprotein levels, liver lipid contents and the area of atherosclerotic plaque were determined respectively.
  
  
  RESULTS
  Compared with model group, TC, TG, LDL-C and ApoB levels were significantly decreased in FTZ groups (P < 0.05 or P < 0.01). The level of HDL-C and the ratio of ApoA I /ApoB were raised significantly (P < 0.05). The contents of TC,TG in liver tissue and the area percentage of atherosclerotic plaque were also markedly reduced (P < 0.05 or P < 0.01) in the FTZ groups.
  
  
  CONCLUSIONS
  FTZ could efficiently regulate the abnormality of lipid metabolism in experimental atherosclerotic rabbits, and this maybe one mamechanisms of its antiatherogenic effect.
authors.affiliation: Guangdong Pharmaceutical University, Guangzhou 510006, China.
authors.forename: Chun-ping
authors.initials: CP
authors.lastname: Tang
authors.forename: Tao
authors.initials: T
authors.lastname: Jiang
authors.forename: Jiao
authors.initials: J
authors.lastname: Guo
authors.forename: Yan-ping
authors.initials: YP
authors.lastname: Wei
authors.forename: Chao-yan
authors.initials: CY
authors.lastname: Yang
authors.forename: Fang-chao
authors.initials: FC
authors.lastname: Chen
mesh_terms: D000818:Animals; D001053:Apolipoproteins / Q000097:blood; D050197:Atherosclerosis / Q000097:blood / Q000188:drug therapy* / Q000517:prevention & control; D002214:Capsules; D002784:Cholesterol / Q000097:blood / Q000378:metabolism; D004195:Disease Models, Animal; D004338:Drug Combinations; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy* / Q000517:prevention & control; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D031659:Ligustrum / Q000737:chemistry; D050356:Lipid Metabolism / Q000187:drug effects*; D008099:Liver / Q000378:metabolism; D008297:Male; D010946:Plants, Medicinal / Q000737:chemistry; D058226:Plaque, Atherosclerotic / Q000473:pathology; D011817:Rabbits; D011897:Random Allocation; D014280:Triglycerides / Q000097:blood* / Q000378:metabolism
chemical_list: D001053:Apolipoproteins; D002214:Capsules; D004338:Drug Combinations; D004365:Drugs, Chinese Herbal; D000960:Hypolipidemic Agents; D014280:Triglycerides; D002784:Cholesterol